HDP 101
Alternative Names: HDP-101; HDP101-ATACLatest Information Update: 06 Jan 2026
At a glance
- Originator Heidelberg Pharma AG
- Class Antineoplastics; Cyclic peptides; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 12 Jun 2025 Updated adverse events and efficacy data from a phase-I/II trial in Multiple myeloma presented at the 30th Congress of the European Haematology Association (EHA-2025)
- 07 Dec 2024 Efficacy and adverse events data from a phase I/II trial on multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
- 01 Oct 2024 Efficacy data from a phase I/IIa trial in Multiple myeloma released by Heidelberg Pharma